Q-omics provides the consensus-scored TRAV28 profile across patient tissues and cancer cell-line models. TRAV28 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TRAV28 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, TRAV28 RNA expression shows 7,934 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where TRAV28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV28 survival associations across molecular data types. TRAV28 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV28 RNA expression–survival associations across cancer types. High TRAV28 expression shows unfavorable associations in MESO, STAD, CHOL, KIRC, UCEC and PCPG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TRAV28 RNA expression.
This table summarizes TRAV28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV28 shows higher tumor expression in KIRC, BLCA, COAD and BRCA. The KIRC box plot shows higher TRAV28 RNA expression in tumor versus normal tissue (log2 FC = +0.224, t-test p < 0.001).
This table shows molecular features associated with TRAV28 in patient tissues and cancer cell lines. In patient samples, TRAV28 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
